Engene names amy pott as chief global commercialization officer

Boston & montreal--(business wire)--engene holdings inc. (nasdaq: engn or “engene” or the “company”), a clinical-stage, non-viral genetic medicines company, today announced the appointment of amy pott as chief global commercialization officer. in this role, ms. pott will serve as the company's first dedicated executive for commercialization planning and execution, reporting to engene's chief executive officer, ron cooper. this appointment marks a significant milestone, as the company expects to.
ENGN Ratings Summary
ENGN Quant Ranking